Vaccination against SARS-CoV-2

PreclinicalBiologic

Vaccination against SARS-CoV-2 is one of 20 biologic programs targeting Severe Acute Respiratory Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

Severe Acute Respiratory SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Severe Acute Respiratory Syndrome

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Approved

1 2

Firazyr

Neoral

Jakafi

Nicorette

Revia

Evista

Veklury

Calciparine

BBaxter Healthcare Corporation

Approved

1 10

Methylthioninium Chloride

PProvepharm SAS

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Acute Respiratory Syndrome1 trial

Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria

Completed·MMedical University of Graz··NCT06162533·9,090,868 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaccination against SARS-CoV-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaccination against SARS-CoV-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaccination against SARS-CoV-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Graz

Vaccination against SARS-CoV-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Severe Acute Respiratory Syndrome1 trial

References

Drug Info

Quick Facts

Related News